HIV and Lenacapavir

Introduction to HIV, and the Antiretroviral Therapy Capsid Inhibitor Lenacapavir

HIV (Human Immunodeficiency Virus) is a major worldwide health issue, producing substantial morbidity and mortality. According to the World Health Organization (WHO), at least 42.3 million [35.7-51.1 million] individuals have died [WHO, 2023] from the illness since June 1981, when the US Centers for Disease Control and Prevention (CDC) reported the first cases of Acquired Immune Deficiency Syndrome (AIDS).   

HIV targets the immune system, primarily CD4+ T cells, depleting them and making the body susceptible to opportunistic infections and malignancies [Tolomeo, 2024]. If left untreated, HIV can proceed to AIDS, which is characterized by severe immunological weakness. According to UNAIDS, 39.9 million [36.1 million-44.6 million] individuals worldwide had HIV in 2023 [UNAIDS, 2024]. Of them, more than 31 million [27-31.9 million] were receiving antiretroviral medication (ART), which has converted HIV into a chronic, treatable disease.  

While traditional ART is beneficial, concerns like as medication resistance, adherence issues, and adverse effects need ongoing innovation in treatment techniques [SeyedAlinaghi, 2023]. Lenacapavir, a new capsid inhibitor, is a promising treatment alternative that offers hope to those with multidrug-resistant HIV [Kumar, 2024]. 

On December 22, 2022, the US FDA authorized Sunlenca® (lenacapavir) for the treatment of HIV-1 infection in people who have been intensively treated (HTE) and have multi-drug resistant (MDR) HIV-1 infection [Ross, 2022].

HIV Overview

HIV is spread by contact with infected body fluids, such as blood, sperm, vaginal fluids, rectal fluid, and breast milk [Nambiar, 2020]. Without treatment, the virus eventually weakens the immune system and causes AIDS. The fundamental objective of HIV treatment is to reduce virus replication, maintain immune function, and prevent transmission.  

ART, or antiretroviral therapy, is a mix of medications that target different phases of the viral lifecycle. While ART is very successful in terms of reducing viral load [Clay, 2018], rigorous adherence is required, since noncompliance can result in medication resistance and treatment failure [Nhlongolwane, 2023]. Long-term ART is also connected with negative effects including as metabolic abnormalities, cardiovascular problems, and bone density loss. These problems underscore the necessity for novel medications such as Lenacapavir [Jemal, 2024].  

Lenacapavir: A Breakthrough in HIV Treatment

Lenacapavir is a long-acting capsid inhibitor that belongs to a novel family of antiretroviral medicines [Prather, 2023]. It acts by targeting the HIV capsid, which is a protein shell that contains the viral RNA and enzymes. The capsid is involved in several phases of the HIV lifecycle, including reverse transcription, nuclear import, and the assembly of new virions [Novikova 2019].  

Lenacapavir decreases viral load and replication by inhibiting these pathways. This drug's unique mechanism of action sets it apart from other antiretroviral medications, making it effective against HIV strains resistant to conventional regimens. [DiPerri, 2023].  

Mechanism of Action

Lenacapavir interacts with certain locations on the HIV capsid protein, hyperstabilising its structure. This artificial stability influences a number of important processes in the viral lifecycle [Faysal, 2024]:

1. Reverse Transcription Inhibition: By interfering with the integrity of the capsid, Lenacapavir prevents viral RNA from being reverse transcribed into DNA, a critical stage in viral reproduction.  

2. Nuclear Import Blockade: The capsid aids in the transfer of viral DNA into the host cell nucleus. Lenacapavir inhibits this mechanism, preventing incorporation into the host DNA.  

3. Maturation Impairment: Lenacapavir hinders the formation of new virions, lowering the number of infectious virus particles.

Advantages of Lenacapavir

Lenacapavir has several advantages over standard ART [Ross, 2022]:  

1. Long-Acting Formulation: Lenacapavir is taken by the patient once every six months, which improves adherence for individuals who struggle with daily or weekly regimens.  

2. Broad-Spectrum Activity: Its novel method of action renders it effective against multidrug-resistant HIV strains, filling a major gap in existing treatment alternatives.  

3. Limited Cross-Resistance: Because Lenacapavir acts by a unique mechanism, it has limited cross-resistance to other antiretroviral medications, allowing it to be added to current treatments to form a more robust regimen.  

4. Enhanced Quality of Life: The reduced frequency of dose and superior safety profile help patients have a better quality of life.

Clinical Development

Lenacapavir has given promising results in clinical studies. The CAPELLA trial, a Phase 2/3 study, examined Lenacapavir in extensively treated people with multidrug-resistant HIV. Participants who received Lenacapavir by subcutaneous injection saw a considerable decrease in viral load, with many reaching undetectable levels [Segal-Maurer, 2022].  

The medication has been investigated in treatment-naïve people and demonstrated significant antiviral activity with a favorable safety profile [Collins, 2022]. Common adverse effects include injection site reactions, nausea, and tiredness, although they are usually moderate and well-tolerated.  

Lenacapavir's long-acting formulation has been a priority in its development [Begley, 2020]. It is administered subcutaneously every six months, providing a convenient alternative to daily oral regimens, lowering treatment burden and enhancing adherence [Gilead, n.d.].

Potential Applications

Lenacapavir's unique features make it suitable for a wide range of HIV control applications:  

1. Salvage Therapy: Lenacapavir is very useful for those with multidrug-resistant HIV who have few therapy choices.  

2. Prevention: Because of its long-acting nature, it has the potential to be used in pre-exposure prophylaxis (PrEP), providing a practical and effective HIV preventive method [WHO, 2024].  

3. Combination Therapy: Lenacapavir can be coupled with other antiretroviral medicines to build powerful regimens suited to each patient's specific requirements.

Challenges and Future Directions

Despite much success leading to FDA approval,  Lenacapavir still faces challenges:

1. Cost: As a novel therapy, Lenacapavir may be significantly more expensive than other ARTs [Hill, 2024], limiting access in low-resource settings where HIV prevalence is highest such as sub-Saharan Africa.

2. Resistance: Although rare, resistance to Lenacapavir could emerge, necessitating ongoing monitoring and development of backup therapies [Collins, 2021].

Future study should focus on improving Lenacapavir's usage in a variety of groups, including pregnant women and children. Studies into its potential in PrEP and combo medicines might broaden its application even more. Efforts to increase accessibility, such as cost reduction and alternate formulations, are crucial for increasing global reach.  

Conclusion

HIV remains a major worldwide health concern, but advances in therapy, such as Lenacapavir, provide fresh hope. As a long-acting capsid inhibitor, Lenacapavir fills key gaps in HIV therapy, especially for people with multidrug-resistant infections. Its novel method of action, broad range efficacy, and easy dosage make it a game-changing addition to the antiretroviral arsenal.  

However, issues such as cost and potential drug resistance must be addressed in order to optimize its influence. With continuous study and innovation, Lenacapavir has the potential to transform HIV management, bringing us closer to the objective of eradicating the HIV epidemic.  

REFERENCES

Begley, R., Lutz, J., Rhee, M., Dvory-Sobol, H., Chiu, A., West, S. K., Corpus, J., Ling, J., & German, P. (2020, July 6-10). Lenacapavir sustained delivery formulation supports 6-month dosing interval. AIDS 2020: 23rd International AIDS Conference. https://www.hivandmore.de/kongresse/iac2020/Begley_LEN-Sustained-delivery-formulation-supports-q6mo-dosing_AIDS2020_PEB0265_Submitted.pdf

Clay, P. G., Yuet, W. C., Moecklinghoff, C. H., et al. (2018). A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Research and Therapy, 15, 1–17. https://doi.org/10.1186/s12981-018-0204-0

Collins, S. (2021, November 30). Lenacapavir: drug resistance after viral rebound in treatment experienced participants. i-base.info. https://i-base.info/htb/41606

Collins, S. (2022, March 1). CROI 2022: Lenacapavir: 54 week results in treatment-naïve participants of CALIBRATE study. i-base. https://i-base.info/htb/42313

Di Perri G. (2023). Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid Inhibitor. Le infezioni in medicina, 31(4), 495–499. https://doi.org/10.53854/liim-3104-8

Faysal, K. M. R., Walsh, J. C., Renner, N., Márquez, C. L., Shah, V. B., Tuckwell, A. J., Christie, M. P., Parker, M. W., Turville, S. G., Towers, G. J., James, L. C., Jacques, D. A., & Böcking, T. (2024). Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure. eLife, 13, e83605. https://doi.org/10.7554/eLife.83605

Gilead. (n.d.). SUNLENCA® (lenacapavir) dosing and administration: HCP Site. SUNLENCA® (lenacapavir). https://www.sunlencahcp.com/dosing-and-administration/sunlenca-dosing/

Hill, A., Levi, J., Fairhead, C., Pilkington, V., Wang, J., Johnson, M., Layne, J., Roberts, D., & Fortunak, J. (2024). Lenacapavir to prevent HIV infection: Current prices versus estimated costs of production. Journal of Antimicrobial Chemotherapy, 79(11), 2906–2915. https://doi.org/10.1093/jac/dkae305

Jemal, M., Ashenef, B., Sinamaw, D., et al. (2024). Metabolic syndrome among people living with HIV on dolutegravir and efavirenz-based antiretroviral therapy in Ethiopia: A comparative cross-sectional study. Journal of the International Association of Providers of AIDS Care, 23, 1–11.
Nambiar, P., & Short, W. R. (2020). Mechanisms of HIV transmission. In W. D. Hardy (Ed.), Fundamentals of HIV medicine 2019 (pp. 1-3). Oxford Academic. https://doi.org/10.1093/med/9780190942496.003.0003

Nhlongolwane, N., & Shonisani, T. (2023). Predictors and barriers associated with non-adherence to ART by people living with HIV and AIDS in a selected local municipality of Limpopo Province, South Africa. Open AIDS Journal, 17, e187461362306220.  http://dx.doi.org/10.2174/18746136-v17-230726-2023-2

Novikova, M., Zhang, Y., Freed, E. O., et al. (2019). Multiple roles of HIV-1 capsid during the virus replication cycle. Virologica Sinica, 34(2), 119–134. https://doi.org/10.1007/s12250-019-00095-3

Prather, C., Lee, A., & Yen, C. (2023). Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV. American Journal of Health-System Pharmacy, 80(24), 1774–1780. https://doi.org/10.1093/ajhp/zxad223

Ravula Tulasi Naga Pavan Kumar, Panja Aishwarya Sai & P. Suma Sri, Boddani Sunil. (2024). Lenacapavir: A novel capsid inhibitor in HIV-1 treatment and capsid inhibitors drugs. International Journal of Pharmaceutical Sciences, 2(11), 961–971. https://doi.org/10.5281/zenodo.14208676

Ross, J., & Smith, M. (2022, December 22). Sunlenca® (lenacapavir) receives FDA approval as a first-in-class, twice-yearly treatment option for people living with multi-drug resistant HIV. Business Wire. https://www.businesswire.com/news/home/20221221005541/en/

Segal-Maurer, S., DeJesus, E., Stellbrink, H. J., Castagna, A., Richmond, G. J., Sinclair, G. I., Siripassorn, K., Ruane, P. J., Berhe, M., Wang, H., Margot, N. A., Dvory-Sobol, H., Hyland, R. H., Brainard, D. M., Rhee, M. S., Baeten, J. M., Molina, J. M., & CAPELLA Study Investigators (2022). Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. The New England journal of medicine, 386(19), 1793–1803. https://doi.org/10.1056/NEJMoa2115542

SeyedAlinaghi, S. A., Afsahi, A. M., Moradi, A., Parmoon, Z., Habibi, P., Mirzapour, P., Dashti, M., Ghasemzadeh, A., Karimi, E., Sanaati, F., Hamedi, Z., Molla, A., Mehraeen, E., & Dadras, O. (2023). Current ART, determinants for virologic failure and implications for HIV drug resistance: An umbrella review. AIDS Research and Therapy, 20(1), 74. https://doi.org/10.1186/s12981-023-00572-6

Tolomeo, M., & Cascio, A. (2024). The Complex Dysregulations of CD4 T Cell Subtypes in HIV Infection. International Journal of Molecular Sciences, 25(14), 7512. https://doi.org/10.3390/ijms25147512

UNAIDS. (2024). Global HIV & AIDS statistics — Fact sheet. UNAIDS.org. https://www.unaids.org/en/resources/fact-sheet

WHO. (2023). Data on the size of the HIV epidemic. World Health Organization. https://www.who.int/data/gho/data/themes/hiv-aids/data-on-the-size-of-the-hiv-aids-epidemic

WHO. (2024, July 26). Long-acting injectable lenacapavir proves effective in HIV prevention for women. World Health Organization. https://www.who.int/news/item/26-07-2024-long-acting-injectable-lenacapavir-proves-effective-in-hiv-prevention-for-women

About the Author:

David Orchard-Webb,

Ph.D., is a technical writer with broad interests including health & technology writing, plus extensive training and knowledge of biomedicine and microbiology. My Ph.D. and postdoc were in oncology and developing cancer medicines. I provide technical medical and other writing services for projects ranging from “knowledge automation” to pure pharma, to food safety, to the history of science, and everything in between. I also provide white papers, ebooks, meta-analysis reviews, editing, consulting, business, and market research-related activities in biomedicine, technology, and health. In addition to its well-known role in the development of medicines, I am a big believer in biotechnology’s ability to revolutionize industries such as food-tech, agtech, textiles & fashion.